20.2 Severe Community-Acquired Pneumonia & Empyema

Severe Community-Acquired Pneumonia: Clinical Stratification

Community-Acquired Pneumonia (CAP) remains the leading infectious cause of hospitalization, critical illness, and mortality in the United States. Recognizing severe CAP is essential, as delayed transfer of deteriorating ward patients to the intensive care unit (ICU) is associated with a dramatic surge in 30-day mortality.

ATS/IDSA Severity Criteria for ICU Admission

The American Thoracic Society (ATS) and Infectious Diseases Society of America (IDSA) established validated severity criteria to guide direct ICU triage. Direct ICU admission is mandated if a patient meets EITHER:

• At least ONE Major Criterion; OR
• At least THREE Minor Criteria.

---

Clinical Risk Scoring: CURB-65 vs. Pneumonia Severity Index (PSI/PORT)

Clinical decision scoring models stratify mortality and assist initial site-of-care decisions:

The CURB-65 Score

A 6-point clinical prediction tool (0 to 5 points):

• C (Confusion): Acute mental status alteration (abbreviated mental test score $\le 8$, or disorientation to person, place, or time) — 1 point
• U (Uremia): Blood urea nitrogen (BUN) $> 19\text{ mg/dL}$ ($> 7\text{ mmol/L}$) — 1 point
• R (Respiratory Rate): Respiratory rate $\ge 30\text{ breaths/min}$ — 1 point
• B (Blood Pressure): Systolic blood pressure $< 90\text{ mm Hg}$ OR diastolic blood pressure $\le 60\text{ mm Hg}$ — 1 point
• 65 (Age): Patient age $\ge 65\text{ years}$ — 1 point

Clinical Distinction: While CURB-65 is rapid and simple to calculate, the Pneumonia Severity Index (PSI / PORT score) is more comprehensive (incorporating 20 clinical, laboratory, and radiographic variables) and carries a superior negative predictive value for identifying low-risk candidates safely managed as outpatients.

---

ICU Antimicrobial Management of Severe CAP

Patients admitted to the ICU with severe CAP require immediate parenteral broad-spectrum antimicrobial therapy initiated within 1 hour of presentation, after obtaining blood cultures and respiratory secretions for microbiological analysis.

1. Standard Empiric ICU Regimen (No MRSA or Pseudomonas Risk Factors)

Standard ICU therapy requires combination parenteral therapy covering Streptococcus pneumoniae (the most common cause of fatal CAP), Legionella pneumophila, Mycoplasma pneumoniae, and Gram-negative enteric bacilli:

$\mathbf{Parenteral\text{ }\beta\text{-Lactam}} \quad + \quad \mathbf{Intravenous\text{ }Macrolide} \quad \text{OR} \quad \mathbf{Intravenous\text{ }Respiratory\text{ }Fluoroquinolone}$

• Parenteral Beta-Lactam Options:
  • Ceftriaxone: $2\text{ g}$ IV every 24 hours (preferred standard dose for severe pneumonia); OR
  • Ampicillin-sulbactam (Unasyn): $3\text{ g}$ IV every 6 hours; OR
  • Cefotaxime: $2\text{ g}$ IV every 8 hours.
• PLUS EITHER:
  • Intravenous Macrolide: Azithromycin $500\text{ mg}$ IV every 24 hours. (Preferred: Extensive observational and trial data show that beta-lactam + macrolide combination yields superior survival over fluoroquinolone monotherapy in severe pneumococcal pneumonia, mediated by the immunomodulatory, anti-inflammatory suppression of cytokine release by macrolides); OR
  • Intravenous Respiratory Fluoroquinolone: Levofloxacin $750\text{ mg}$ IV every 24 hours (or Moxifloxacin $400\text{ mg}$ IV every 24 hours).

2. Risk-Stratified Coverage for MRSA and Pseudomonas aeruginosa

The 2019 ATS/IDSA guidelines abandoned the prior "Healthcare-Associated Pneumonia (HCAP)" categorization. Routine empiric broad-spectrum MRSA and Pseudomonas coverage is NO LONGER RECOMMENDED for all severe CAP admissions. Instead, empiric coverage is added strictly based on validated pathogen-specific risk factors:

• Indications for Empiric Anti-MRSA Coverage:

  1. Prior respiratory isolation of Methicillin-Resistant Staphylococcus aureus (MRSA);
  2. Recent hospitalization AND receipt of parenteral antibiotics within the preceding 90 days;
  3. Clinical presentation of post-viral necrotizing pneumonia (e.g., severe necrotizing cavitary pneumonia following acute influenza, characterized by hemoptysis, leukopenia, and septic shock driven by Panton-Valentine leukocidin [PVL] producing MRSA strains).
  • Therapeutic Agents:
    • Vancomycin: $15\text{ to }20\text{ mg/kg}$ IV every 8 to 12 hours, targeting an AUC/MIC ratio of $400\text{ to }600$ (or trough concentration $15\text{ to }20\text{ mcg/mL}$); OR
    • Linezolid: $600\text{ mg}$ IV every 12 hours. (Linezolid is clinically preferred in suspected toxin-producing PVL necrotizing staphylococcal pneumonia because it inhibits ribosomal protein synthesis, halting bacterial exotoxin production).
  • Diagnostic Stewardship: Perform an MRSA nasal PCR screen on admission. The MRSA nasal PCR possesses a $96%\text{ to }99%$ negative predictive value; if the nasal screen is negative, vancomycin or linezolid can be safely and definitively discontinued within 24 to 48 hours.

• Indications for Empiric Anti-Pseudomonal Coverage:

  1. Prior respiratory isolation of Pseudomonas aeruginosa;
  2. Recent hospitalization AND receipt of parenteral antibiotics within the preceding 90 days;
  3. Underlying severe structural lung disease (e.g., severe cystic fibrosis, severe bronchiectasis, or advanced COPD with frequent exacerbations requiring chronic systemic steroids and recurrent antibiotics).
  • Therapeutic Agents:
    • Cefepime: $2\text{ g}$ IV every 8 hours; OR
    • Piperacillin-tazobactam (Zosyn): $4.5\text{ g}$ IV every 6 hours (administered as an extended 4-hour infusion); OR
    • Meropenem: $1\text{ g}$ IV every 8 hours.

3. Adjunctive Systemic Corticosteroids (The CAPE COD Trial)

The 2023 Community-Acquired Pneumonia: Evaluation of Corticosteroids (CAPE COD) multicenter double-blind randomized trial evaluated early adjunctive corticosteroid therapy in adults admitted to the ICU with severe CAP:

• Intervention: Intravenous Hydrocortisone ($200\text{ mg/day}$ continuous infusion or $50\text{ mg}$ IV every 6 hours for 4 to 8 days, followed by a taper).
• Findings: Hydrocortisone significantly reduced 28-day all-cause mortality from $11.9%$ in the placebo group to $6.2%$ in the hydrocortisone group ($p = 0.006$), representing an absolute risk reduction of $5.7%$ (number needed to treat [NNT] = 18). Furthermore, it reduced the rate of invasive mechanical ventilation and vasopressor requirements without increasing secondary nosocomial infections.
• Guideline Integration: Early IV hydrocortisone is now strongly recommended in adults admitted to the ICU with severe CAP who have systemic inflammation and no contraindications.

---

Parapneumonic Effusion & Pleural Empyema

A parapneumonic effusion is any pleural effusion associated with bacterial pneumonia, lung abscess, or bronchiectasis, occurring in $20%\text{ to }40%$ of hospitalized pneumonia patients.

Diagnostic Thoracentesis Indication

• The 10-mm Rule: A diagnostic thoracentesis must be performed promptly for any parapneumonic effusion measuring $> 10\text{ mm}$ (or $> 1\text{ cm}$) in depth on a lateral decubitus chest radiograph or bedside thoracic ultrasound.
• Effusions $< 10\text{ mm}$ are statistically unlikely to yield adequate diagnostic fluid and usually resolve with systemic antibiotic therapy alone.

Light's Criteria for Exudative Pleural Effusion

Light's criteria are the gold standard for differentiating an exudate (reflecting local pleural inflammation or increased vascular permeability) from a transudate (reflecting systemic imbalance of hydrostatic or oncotic pressure, such as heart failure or cirrhosis):

$\text{An effusion is classified as an } \mathbf{EXUDATE} \text{ if it meets } \mathbf{\ge 1} \text{ of the following 3 criteria:}$

1. Pleural fluid protein / Serum protein ratio $> 0.5$
2. Pleural fluid LDH / Serum LDH ratio $> 0.6$
3. Pleural fluid LDH $> \frac{2}{3}$ the institutional upper limit of normal (ULN) serum LDH (typically $> 160\text{ to }200\text{ U/L}$)

---

Staging and Management of Parapneumonic Effusions

                    PARAPNEUMONIC EFFUSION STAGING SPECTRUM

  ┌─────────────────────────────────────────────────────────────────────────────────┐
  │ STAGE 1: SIMPLE (UNCOMPLICATED) PARAPNEUMONIC EFFUSION                          │
  ├─────────────────────────────────────────────────────────────────────────────────┤
  │ • Pathophysiology: Sterile inflammatory exudate; intact mesothelial barrier      │
  │ • Fluid Analysis: Clear/serous, pH >7.20, Glucose >60 mg/dL, LDH <1000 U/L      │
  │ • Microbiology: Gram stain and bacterial cultures are NEGATIVE                  │
  │ • MANAGEMENT: Systemic IV antibiotics ALONE; NO chest tube drainage required   │
  └───────────────────────────────────────┬─────────────────────────────────────────┘
                                          │ Bacterial invasion of pleural space
                                          │ Neutrophil glycolysis & lactic acid
                                          ▼
  ┌─────────────────────────────────────────────────────────────────────────────────┐
  │ STAGE 2: COMPLICATED PARAPNEUMONIC EFFUSION (Fibrinopurulent)                   │
  ├─────────────────────────────────────────────────────────────────────────────────┤
  │ • Pathophysiology: Bacterial invasion, heavy neutrophil influx, fibrin septa    │
  │ • Fluid Analysis: Turbid, pH <7.20, Glucose <40-60 mg/dL, LDH >1000 U/L         │
  │ • Microbiology: Gram stain / culture may be positive or sterile                │
  │ • MANAGEMENT: MANDATORY IMMEDIATE TUBE THORACOSTOMY (CHEST TUBE) DRAINAGE       │
  └───────────────────────────────────────┬─────────────────────────────────────────┘
                                          │ Dense organization, thick fibrin peel,
                                          │ non-draining loculations
                                          ▼
  ┌─────────────────────────────────────────────────────────────────────────────────┐
  │ STAGE 3: FRANK EMPYEMA (Organizing Stage)                                       │
  ├─────────────────────────────────────────────────────────────────────────────────┤
  │ • Pathophysiology: Frank macroscopic pus, thick gelatinous peel, trapped lung    │
  │ • Fluid Analysis: Frank pus, turbid white/yellow, pH <7.00, Glucose <20 mg/dL   │
  │ • Microbiology: Frank pus or Gram stain / bacterial culture POSITIVE            │
  │ • MANAGEMENT: MANDATORY IMMEDIATE CHEST TUBE DRAINAGE                            │
  │   + Intrapleural tPA/DNase (MIST-2) for loculations vs VATS Decortication       │
  └─────────────────────────────────────────────────────────────────────────────────┘

Diagnostic Criteria Summary Table

Pathophysiologic Pearl: The dramatic decline in pleural fluid pH ($< 7.20$) and glucose ($< 40\text{ mg/dL}$) in complicated effusions and empyema is driven by accelerated anaerobic glycolysis by activated neutrophils and proliferating pleural bacteria, which generate high concentrations of lactic acid and consume available glucose. A pleural pH $< 7.20$ is the single most powerful and sensitive predictor of failure with antibiotics alone.

---

Intrapleural Fibrinolytic & Deoxyribonuclease (DNase) Therapy: The MIST-2 Trial

When a complicated parapneumonic effusion or empyema develops multiple fibrinous septations, dense loculations, or fails to evacuate completely through a correctly positioned chest tube:

• The Failure of Monotherapy (The MIST-1 Trial):
  • The initial MIST-1 trial established that intrapleural streptokinase monotherapy conferred zero clinical benefit (no reduction in mortality or need for surgery) and caused adverse bleeding events.
• The Synergistic Solution: Combination tPA + DNase (The MIST-2 Trial):
  • The landmark Second Multicenter Intrapleural Sepsis Trial (MIST-2) demonstrated that the combination of recombinant tissue plasminogen activator (tPA / alteplase) and recombinant human deoxyribonuclease (DNase / dornase alfa) produces dramatic therapeutic synergy:
    • tPA ($10\text{ mg}$) breaks down dense fibrin strands and intrapleural loculations.
    • DNase ($5\text{ mg}$) enzymaticly cleaves free extracellular DNA released by degenerating, necrotic neutrophils, which is the primary molecular factor responsible for extreme pus viscosity.

The Evidence-Based MIST-2 Protocol

• Dosing Schedule:
  • tPA ($10\text{ mg}$) dissolved in $50\text{ mL}$ normal saline instilled into the chest tube;
  • Followed immediately by DNase ($5\text{ mg}$) dissolved in $50\text{ mL}$ normal saline instilled into the chest tube;
  • The chest tube is clamped for 1 to 2 hours to allow intrapleural dwell and enzymatic cleavage, then reconnected to $-20\text{ cm }H_2O$ suction;
  • Administered twice daily for 3 consecutive days (total 6 doses).
• Trial Outcomes:
  • $77%$ Reduction in Surgical Intervention: Reduced referral for surgical decortication from $16%$ to $4%$ (odds ratio $0.17$, $p = 0.005$).
  • Marked Radiographic Clearance: Significant reduction in radiographic pleural opacities (mean change $-29.5%$ vs $-17.2%$ with placebo, $p < 0.001$).
  • Decreased Hospital Stay: Shortened median length of hospital stay by $6.7\text{ days}$ ($p = 0.003$).
  • Monotherapy Failure: The trial proved that tPA alone or DNase alone showed no significant reduction in surgical referral or hospital length of stay compared to placebo.

Indications for Surgical Intervention (VATS Decortication)

Video-Assisted Thoracoscopic Surgery (VATS) decortication is indicated if:

1. Intrapleural tPA/DNase therapy fails to achieve adequate pleural clearance and clinical sepsis persists after 72 hours (6 doses);
2. Thick fibrous pleural peel forms, producing a "trapped lung" that prevents normal pulmonary re-expansion;
3. Presence of bronchopleural fistula or massive multi-compartment chronic organizing empyema.